



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Extended-Release Opioid Analgesics Page: 1 of 5

Effective Date: 5/28/2025 Last Review Date: 5/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for extended-release opioid analgesics under the patient's prescription drug benefit.

Description:

The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines for extended-release opioid analgesics. The American Pain Society Opioid Treatment Guidelines state that a reasonable definition for high dose opioid therapy is greater than 200 mg daily of oral morphine (or equivalent). Requests to exceed these limits and those for any non-preferred product are subject to the criteria in this policy. Medications requested for more than 200 Morphine Milligram Equivalents (MME) per day will require a Medical Director Review.

Applicable Drug List:

Fentanyl Transdermal Patch

Hydrocodone bitartrate 12 Hour ER Capsule

Hydrocodone bitartrate 24 Hour ER Tablet
(Generic Hysingla ER)

Hydromorphone HCL 24 Hour ER Tablet
(Generic Exalgo)

Methadone HCL Tablet

Methadone HCL Oral Solution

Methadone HCL Oral Concentrate
(Generic Methadose)

Morphine Sulfate 12 Hour ER Tablet
(Generic MS Contin)

Morphine Sulfate 24 Hour ER Capsule
(Generic Kadian)



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Extended-Release Opioid Analgesics Page: 2 of 5

Effective Date: 5/28/2025 Last Review Date: 5/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

Morphine Sulfate 24-hour ER Beads Capsule
(Generic Avinza)

Xtampza (oxycodone 12 Hour ER Capsule)

Oxycodone HCL 12 Hour ER Tablet
(Generic oxycontin)

Oxymorphone HCL 12-hour ER Tablet
(Generic Opana ER)

Nucynta ER (tapentadol HCL 12-hour ER Tablet)

Tramadol HCL 24-hour Biphaseic Release Capsule
(Generic Conzip)

Tramadol HCL 24 Hour ER Tablet
(Generic Ultram ER)

Tramadol HCL 24 Hour Biphaseic Release Tablet

Buprenorphine Transdermal Patch
(Generic Butrans)

Buprenorphine HCL Buccal Film
(Generic Belbuca)

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for pain associated with cancer, sickle cell disease, a terminal condition, or pain being managed through hospice or palliative care

AND

- If the request is for a nonpreferred extended-release opioid analgesic, the patient is unable to take the required number of formulary alternatives for the given diagnosis due to a trial and inadequate treatment response or intolerance, or a contraindication. Documentation is required for approval.

OR



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Extended-Release Opioid Analgesics	Page:	3 of 5
Effective Date:	5/28/2025	Last Review Date:	5/2025
Applies to:	<input checked="" type="checkbox"/> Illinois <input type="checkbox"/> New Jersey <input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Florida <input type="checkbox"/> Maryland <input type="checkbox"/> Virginia	<input checked="" type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan <input type="checkbox"/> Kentucky PRMD

- The requested drug is being prescribed for CHRONIC pain severe and persistent enough to require an extended treatment period with a daily opioid analgesic in a patient who has been taking an opioid [Note: Chronic pain is generally defined as pain that typically lasts greater than 3 months.]
AND
- The patient can safely take the requested dose based on their history of opioid use
AND
- The patient has been evaluated and the patient will be monitored regularly for the development of opioid use disorder
AND
- The patient’s pain will be reassessed in the first month after the initial prescription or any dose increase **AND** every 3 months thereafter to ensure that clinically meaningful improvement in pain and function outweigh risks to patient safety
AND
- This request is for continuation of therapy for a patient who has been receiving an extended-release opioid agent for at least 30 days **OR**
- The patient has taken an immediate-release opioid for at least one week
AND
- If the request is for a methadone product, then it is NOT being prescribed for detoxification treatment or as part of a maintenance treatment plan for opioid/substance abuse or addiction
AND
- If the request is for a nonpreferred extended-release opioid analgesic, the patient is unable to take the required number of formulary alternatives for the given diagnosis due to a trial and inadequate treatment response or intolerance, or a contraindication. Documentation is required for approval.

[Note: These drugs should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.]

Quantity Limits may apply.

Approval Duration and Quantity Restrictions:

For pain associated with cancer, sickle cell disease, a terminal condition, or pain being managed through hospice or palliative care: Approve: 12 months

Chronic pain: Approve: 6 months



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Extended-Release Opioid Analgesics Page: 4 of 5

Effective Date: 5/28/2025 Last Review Date: 5/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. Belbuca [package insert]. Stoughton, MA: Collegium Pharmaceutical, Inc.; December 2023.
2. Butrans [package insert]. Stamford, CT: Purdue Pharma L.P.; December 2023.
3. ConZip [package insert]. Alpharetta, GA: Vertical Pharmaceuticals, LLC.; December 2023.
4. Fentanyl Transdermal [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; October 2024.
5. Hydrocodone ER capsules [package insert]. Morristown, NJ: Alvogen, Inc.; December 2023.
6. Hydromorphone ER [package insert]. Minneapolis, MN: Padagis; January 2024.
7. Hysingla ER [package insert]. Stamford, CT: Purdue Pharma L.P.; December 2023.
8. Methadone Injection [package insert]. Morgantown, WV: Mylan Institutional LLC; December 2023.
9. Methadone Hydrochloride Oral Concentrate (Intensol) [package insert]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc.; March 2024.
10. Methadone Oral Solution [package insert]. Webster Groves, MO: SpecGx LLC; January 2024.
11. Methadone Tablets [package insert]. Webster Groves, MO: SpecGx, LLC; December 2023.
12. Morphine ER Capsules [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC.; February 2024.
13. Morphine ER Capsules [package insert]. Parsippany, NJ: Teva Pharmaceuticals; November 2023.
14. MS Contin [package insert]. Stamford, CT: Purdue Pharma L.P.; December 2023.
15. Nucynta ER [package insert]. Stoughton, MA: Collegium Pharmaceutical, Inc; December 2023.
16. OxyContin [package insert]. Stamford, CT: Purdue Pharma L.P.; December 2023.
17. Oxymorphone ER [package insert]. Brookhaven, NY: Amneal Pharmaceuticals of NY, LLC; August 2022.
18. Tramadol extended-release tablets [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; December 2023.
19. Tramadol extended-release tablets [package insert]. Baltimore, MD: Lupin Pharmaceuticals, Inc.; January 2024.
20. Xtampza ER [package insert]. Cincinnati, OH: Patheon Pharmaceuticals; December 2023.
21. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed November 20, 2024.
22. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 11/20/2024).
23. Dowell D, Ragan, KR, Jones, CM, et al; CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. MMWR Recomm Rep. 2022;71:1–95. Available at: <http://dx.doi.org/10.15585/mmwr.rr7103a1>. Accessed November 21, 2024.
24. Palliative Care. NCCN Guidelines version 1.2025. Available at: https://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf. Accessed November 21, 2024.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Extended-Release Opioid Analgesics Page: 5 of 5

Effective Date: 5/28/2025 Last Review Date: 5/2025

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

25. Adult Cancer Pain. NCCN Guidelines version 3.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed December 9, 2024.
26. Chou R, Fanciullo G, Fine P, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. *The Journal of Pain*. 2009;10:113-130.
27. National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. Available at: https://www.nhlbi.nih.gov/sites/default/files/media/docs/sickle-cell-disease-report%2020816_0.pdf. Accessed November 21, 2024.
28. U.S. Food & Drug Administration. FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use. April 13, 2023. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use>. Accessed November 21, 2024.